【Asset for Licensing】Novel LIV-1-targeted ADC armed with optimized TOPO1 inhibitor payload

Asset: Novel LIV-1-targeted ADC armed with optimized TOPO1 inhibitor payload
Development Stage: IND stage
Indication: Triple-Negative Breast Cancer (TNBC) and HR-positive/HER2-negative Breast Cancer
Key Asset Highlights:
（1）Represents a mono-targeting LIV-1 ADC integrated with a validated and clinically mature TOPO1 inhibitor payload, optimized to address unmet therapeutic challenges in heterogeneous breast cancer subtypes.
（2）Specifically targets LIV-1, a zinc transporter protein highly and selectively overexpressed in TNBC and HR+ HER2- breast cancer, enabling precise tumor enrichment and effective minimization of off-tumor toxicity.
（3）Following antigen-mediated internalization, the conjugated TOPO1 inhibitor payload is efficiently released within tumor cells, triggering potent DNA damage, cell cycle arrest, and robust tumor cytotoxicity.
（4）Demonstrates superior differentiated anti-tumor potency against refractory and recurrent breast cancer lesions, overcoming the therapeutic limitations of conventional targeted agents and endocrine therapies.
（5）Features optimized linker configuration, stable drug-to-antibody ratio and a favorable safety window, ensuring high clinical translatability and supporting subsequent clinical advancement.
（6）Protected by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for LIV-1-positive breast cancer treatment.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.